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Type I interferons (IFNs) were first characterized in the process of viral interference. 
However, since then, IFNs are found to be involved in a wide range of biological pro-
cesses. In the mouse, type I IFNs comprise a large family of cytokines. At least 12 IFN-α 
and one IFN-β can be found and they all signal through the same receptor (IFNAR). A 
hierarchy of expression has been established for type I IFNs, where IFN-β is induced 
first and it activates in a paracrine and autocrine fashion a cascade of other type I IFNs. 
Besides its importance in the induction of the IFN cascade, IFN-β is also constitutively 
expressed in low amounts under normal non-inflammatory conditions, thus facilitating 
“primed” state of the immune system. In the context of cancer, type I IFNs show strong 
antitumor function as they play a key role in mounting antitumor immune responses 
through the modulation of neutrophil differentiation, activation, and migration. Owing to 
their plasticity, neutrophils play diverse roles during cancer development and metasta-
sis since they possess both tumor-promoting (N2) and tumor-limiting (N1) properties. 
Notably, the differentiation into antitumor phenotype is strongly supported by type I IFNs. 
It could also be shown that these cytokines are critical for the suppression of neutro-
phil migration into tumor and metastasis site by regulating chemokine receptors, e.g., 
CXCR2 on these cells and by influencing their longevity. Type I IFNs limit the life span of 
neutrophils by influencing both, the extrinsic as well as the intrinsic apoptosis pathways. 
Such antitumor neutrophils efficiently suppress the pro-angiogenic factors expression, 
e.g., vascular endothelial growth factor and matrix metallopeptidase 9. This in turn 
restricts tumor vascularization and growth. Thus, type I IFNs appear to be the part of the 
natural tumor surveillance mechanism. Here we provide an up to date review of how type 
I IFNs influence the pro- and antitumor properties of neutrophils. Understanding these 
mechanisms is particularly important from a therapeutic point of view.
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iNTRODUCTiON
The significance of type I interferons (IFNs) in cancer immune surveillance is well established by 
now. These cytokines were first characterized late in the 1950s as cytokines with antiviral activity (1). 
In the mouse, type I IFNs comprise a large family of cytokines with at least 12 IFN-α, IFN-β, IFN-ε 
and IFN-κ (2, 3). All of them signal via a common receptor IFNAR, and they induce the expression 
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of several 100 IFN-inducible genes and have a broad range of 
biological functions (2). Within the type I IFNs, IFN-α and IFN-
β are best characterized. Importantly, a hierarchy of expression 
has been shown to exist for these cytokines (4, 5), where IFN-β 
is induced first. When it binds to IFNAR, IFN-β in a paracrine 
and autocrine fashion triggers a cascade of type I IFNs, including 
IFN-α and IFN-β. The only exception to this rule are plasmacy-
toid dendritic cells (pDCs), which can start immediately with the 
secretion of IFN-α (6). Besides, its importance for the induction 
of the IFN cascade, IFN-β is also constitutively expressed in low 
amounts under normal non-inflammatory conditions (7). This 
was clearly demonstrated by non-invasive imaging using the new 
luciferase reporter mouse, but also by ex vivo determination of 
the enzymatic activity of luciferase in various tissues (4). The 
reason for such constitutive expression of IFN-β might be the 
priming of the immune system to persist in a pre-activated state 
that guarantees a faster and stronger type I IFNs response when 
necessary. Notably, using luciferase reporter mouse, it could be 
demonstrated that growing tumors induce type I IFNs expression 
mainly in tumor-infiltrating dendritic cells (DCs) (8).
Besides their role in antiviral and antimicrobial responses, 
type I IFNs shape innate and adaptive immunity (9), influence 
the maintenance of cellular homeostasis (10), hematopoiesis 
(11), and lymphocyte development (12). In addition, type I IFNs 
show strong antitumor activity (13) and are involved in cancer 
immunoediting (14). The mechanisms of how type I IFNs con-
tribute to the immune surveillance against tumors are not fully 
understood, notwithstanding their beneficial effects in the cancer 
therapy (13). In the context of cancer, type I IFNs were found to 
play a key role in supporting host immune responses through the 
activation of multiple immune cells, e.g., T-cells, natural killer 
(NK) cells, DCs, and macrophages. In recent years, it has become 
apparent that type I IFNs affect also neutrophil activation and 
promote antitumor functions of these cells.
The inflammation has been recently associated with increased 
susceptibility for cancer (15). Consequently, neutrophils as 
a central component of this process play an essential role in 
inflammation-driven tumorigenesis. Moreover, neutrophils 
represent an independent prognostic marker in a broad variety of 
neoplasias. In the past, these cells were viewed as solely dedicated 
to phagocytosis and the production of reactive oxygen species 
(ROS). Now, they are recognized for an extreme versatility with 
regard to function (16, 17) and play manifold roles during tumor 
development (8, 18). Neutrophils affect primary tumor growth 
by influencing its angiogenesis (18), but also by direct killing of 
tumor cells (8). Moreover, neutrophils can facilitate the spread of 
tumor cells to distant organs in a process called metastasis (19, 
20). Neutrophils are apparently controlled by factors produced 
by the primary tumor and are responsible for the preference of 
metastasizing tumor cells to certain organs. Type I IFNs have a 
substantial influence on this process (20).
The tumor microenvironment represents a special niche that 
is extremely influencing infiltrating immune cells. The concept of 
immune cell polarization was described initially for macrophages 
(antitumor M1/pro-tumor M2), but recently polarization of 
neutrophils is getting growing attention. Neutrophils appear to 
have contradicting phenotypes in the tumor microenvironment, 
i.e., tumor promoting (N2) or inhibiting (N1) (16), depending 
on the cytokine milieu in the tumor. Cytokines that are known 
to control neutrophil polarization are type I IFNs, driving 
neutrophil differentiation into N1 antitumor state (8). Of note, 
strict classification into N1 or N2 phenotypes is certainly an 
oversimplification. More likely, these two immune phenotypes 
spot the end points of a continuum of functional states exhibited 
by neutrophils in tumor milieu, which can be regulated by the 
environmental cues. Here, we provide an up to date review of 
how type I IFNs influence the pro- and antitumor properties of 
neutrophils.
TUMOR MiCROeNviRONMeNT AND  
THe PHeNOTYPe OF NeUTROPHiLS
Tumor cells, as well as infiltrating immune cells, produce wide 
range of cytokines, chemokines, and growth factors. This leads 
to the activation and recruitment of other immune cells, such as 
neutrophils, monocytes, and lymphocytes. Moreover, the tumor 
microenvironment plays a significant role in the differentiation 
and functional properties of such cells. In the early steps of 
tumorigenesis, the infiltration of immune cells into the tumor 
tissue serves as one of the tumor killing mechanisms and provides 
protection against tumor progression. When this line of defense is 
insufficient and tumor escapes the immune response, the balance 
shifts to suppressive anti-inflammatory microenvironment. This 
effect was initially described and widely studied for macrophages 
and their polarization into antitumor M1 and pro-tumor M2 
(21–26).
Neutrophils were previously thought to be terminally dif-
ferentiated, short lived myeloid cells. Recent studies, however, 
confirmed that tumor-associated neutrophils (TANs) can also 
exhibit antitumor N1 or pro-tumor N2 properties, similarly to 
macrophages (16). The different role of such neutrophil pheno-
types in tumor progression and their influence on the prognosis 
of the disease were assessed. Some studies revealed strong 
antitumor properties of neutrophils (27), including antibody-
dependent or direct cytotoxicity (28) mediated by ROS release 
(29) and production of neutrophil extracellular traps (NETs) (8). 
Moreover, neutrophils potentiate antitumor immune responses 
by the recruitment of other immune cells to the tumor site (30). 
Recently, the role of neutrophils as possible antigen-presenting 
cells (APCs) was suggested. These cells were shown to modulate 
activation of CD4+ and CD8+ T cells via expression of costimula-
tory molecules like CD86, ICAM-1, OX40L, and 4-1BBL (31–33).
At the same time, tumor-supporting activities of neutrophils 
were revealed, demonstrating the role of these cells as efficient 
inhibitors of host immunosurveillance. Moreover, neutrophils 
were shown to stimulate tumor angiogenesis via secretion of 
vascular endothelial growth factor (VEGF) and matrix metallo-
peptidase 9 (MMP9) (18). This leads to the better vascularization 
of the primary tumor and its growth. Of note, not only primary 
tumor growth is maintained by neutrophils, but also the forma-
tion of metastases can be enhanced by these cells. Pro-tumor 
neutrophils upregulate the expression of pro-metastatic proteins, 
e.g., Bv8, S100A8, and S100A9, but also VEGF and MMP9 in 
pre-metastatic lungs of IFN-deficient mice. This phenomenon, 
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together with the enhanced infiltration of lungs by these cells, 
leads to improved metastatic load in IFN-deficient mice (20). N2 
neutrophils are characterized with immature nucleus shape and 
reduced tumor cell killing capacity (34); they were also shown to 
recruit regulatory T cells in tumors by expression of CCL17 (35). 
Accordingly, in clinical studies, the percentage of neutrophils in 
blood and neutrophil/lymphocyte ratio was shown to be negative 
predictors of patient outcome in different types of cancer (36, 37).
Although two functionally different types of neutrophils were 
described, clear markers allowing distinguishing pro- and antitu-
mor neutrophils are still not available. Nevertheless, factors that 
determine the phenotype shift are in general similar to those for 
macrophages (16). Type I IFNs are considered as N1-promoting 
cytokines and transforming growth factor beta (TGF-β) has 
been suggested to be N2 inducer (38). TGF-β is a well-known 
immunosuppressive cytokine, expressed also in tumors, which 
circulating form was shown to correlate with tumor progression 
(39). The functional antagonism between type I IFNs and TGF-β 
is observed not only for neutrophils but also was shown for human 
peripheral blood mononuclear cells (40) and it could be due to 
the antagonisms between signaling pathways of these cytokines. 
Smad2 and Smad3, the downstream molecules of the TGF-β 
signal transduction pathway, were shown to negatively regulate 
LPS-induced macrophage activation by suppressing multiple 
steps in the IFN-β/STAT1 pathway, including the inhibition 
STAT1 transcriptional activity (41). Similar results were shown 
for myeloid cells of the central nervous system (CNS), where 
TGF-β impaired the ability of such cells to acquire a resolving 
anti-inflammatory phenotype via downregulation of IFN regula-
tory factor 7 (IRF7) (42). Thus, TGF-β may potentially influence 
neutrophil type I IFN-dependent functions and polarization by 
modulation of STAT1 pathway. Nevertheless, the regulation of 
type I IFN and TGF-β pathways seems to be more complicated 
since a positive crosstalk between IFN-α and TGF-β signaling 
was observed in preneoplastic rat liver, resulting in activation of 
both; STAT1 and Smad2/3 pathways (43).
Deficiency in endogenous type I IFN signaling seems to play a 
significant role in the switch of immune response from antitumor 
to pro-tumor one. Moreover, there is an evidence of changing 
phenotype of TANs with a shift to pro-tumorigenic properties 
during tumor progression (44), which can be explained with 
continuous fluctuation of cytokines and chemokines.
Of note, an alternative concept of anti-inflammatory low-
density neutrophils (LDNs) and pro-inflammatory high-density 
neutrophils (HDNs) in tumor situation emerged recently (45). 
Due to the literature, HDNs represent a homogenous population 
of mature segmented neutrophils, while LDN population consists 
of both immature (banded/MDSC) and mature neutrophils. 
HDNs are characterized as cells with high cytotoxicity against 
tumors while LDNs have no cytotoxicity, representing the pro-
tumor neutrophils subset (45). Yet, there is no comprehensive 
data showing the influence of type I IFNs on the LDL/HDL bal-
ance in the tumor-bearing hosts. The current knowledge on the 
heterogeneous populations of mature and immature neutrophils, 
including LDNs, low-density granulocytes (LDGs), granulocytic 
myeloid-derived suppressor cells (G-MDSCs), and immunosup-
pressive neutrophils is summarized recently by Scapini et al. (46).
eNDOGeNOUS TYPe i iFN SiGNALiNG  
iN NeUTROPHiLS
The receptor of type I IFNs (IFNAR) belongs to the family of type 
II cytokine receptors that trigger the activation of the JAK-STAT 
pathway. Ligand that binds to the receptor activates the cascade of 
phosphorylation of JAK molecules, which in turn phosphorylate 
tyrosine residues on the receptor chains leading to the subsequent 
STAT protein phosphorylation and activation. IFNAR primarily 
utilizes JAK1 with some accessory role for JAK2 and TYK2, and 
activates STAT1, STAT2, or STAT3 pathways. Phosphorylated 
STAT proteins undergo dimerization and shuttle to the nucleus 
where they bind promoter regions and regulate gene transcrip-
tion (47). Type II cytokine receptors are involved in a number of 
neutrophil function including regulation of survival, differentia-
tion, and activation (48–50). Different expression of mediating 
proteins and the regulation of intracellular signal transduction 
pathways determine the final effect of type I IFNs under certain 
conditions (51). STAT1/STAT3 functional imbalance with the 
shift to STAT3 activation and following antiapoptotic protein 
expression is known to be crucial for tumorigenesis (52). In this 
case, IFN-β was shown to suppress cancer growth and metastasis 
rate through inhibition of STAT3 signaling in tumor cells (53).
In the context of cancer, type I IFNs show strong antitumor 
properties. IFN gene therapy was associated with sustained local 
production of IFN-β that efficiently suppressed tumor growth in 
prostate and bladder cancer as well as melanoma, renal cell carci-
noma, and colon carcinoma (54–56). This effect was ascribed to 
the induction of tumor cell apoptosis (57) and the inhibition of 
tumor angiogenesis due to decreased VEGF expression in differ-
ent tumors (58, 59).
A new line of studies devoted to the effects of IFNs in tumor 
conditions was induced by the growing evidence that the immune 
system plays a significant role in the regulation of oncogen-
esis. Type I IFNs were shown to stimulate antitumor immune 
responses via several mechanisms reviewed by Parker et  al., 
including enhancement of immune recognition of tumor cells by 
upregulation of major histocompatibility complex (MHC) class I 
and tumor antigen expression on tumor cell surface, increasing 
NK cytotoxicity, and switching macrophage phenotype from M2 
to M1 (60). Moreover, antigen-presenting properties of DCs were 
shown to be improved, effector T cell proliferation enhanced, 
and suppressive activity of regulatory T cells reduced by these 
cytokines.
Neutrophils lately are being recognized as key players that 
regulate tumorigenesis and metastatic processes, modulation 
of their differentiation and activation by type I IFNs becomes 
an important area of research. The absence of endogenous 
type I IFN signaling results in shift of neutrophil phenotype to 
tumor-supporting one. Several factors can be responsible for this 
phenomenon, including genetic peculiarities of molecular signal-
ing pathways (61, 62), maturation state of the neutrophils, and 
exogenous influence. While the genes for intracellular proteases 
and other cytotoxic proteins were shown to be expressed at earlier 
stages of maturation, the genes for proteins responsible for signal 
transduction from IFNAR, and, therefore, mediating the release 
of abovementioned cytotoxic factors, are preferentially induced 
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during terminal differentiation (63). Immature state of circulat-
ing human neutrophils exposed to granulocyte/macrophage 
colony-stimulating factor (GM-CSF) in vitro was characterized 
with downregulation of IFN signaling pathway, including IFNAR, 
IFN-γ receptor as well as JAK1, JAK2, STAT1, and STAT2 (63). 
Colony-stimulating factors are usually overexpressed in tumor 
environment. Considering the fact that these factors induce the 
release of immature neutrophils from the bone marrow (BM) 
as well as support the immunosuppressive state in circulation 
(64–66), one can expect a downregulation of IFN-mediated sig-
nal transduction pathways and decreased efficiency of antitumor 
immune responses in the presence of such growth factors. Similar 
feedback loop was described for VEGF, one of the factors sup-
porting tumor angiogenesis, which is capable to downregulate 
IFNAR expression (67).
Although type I and type II IFN signaling pathways share 
common intracellular mediators, e.g., STAT1, STAT2, and 
STAT3, they are shown to exhibit different regulatory role 
in tumorigenesis. While IFN-γ is known mainly as an agent 
regulating tumor cell survival, type I IFNs primarily modulate 
host immune responses against tumors (68). The exclusive effect 
of type I IFNs on the host immune system was also confirmed 
by studies of Wu et al. that could demonstrate enhanced tumor 
growth in animals lacking IFNAR but able to produce endog-
enous type I IFNs (20). In this case, tumor growth was similarly 
enhanced as in IFN-β-deficient animals. The constitutive lack of 
endogenous IFN-β (Ifnb1−/− mice) as well as the lack of type I IFN 
signaling (Ifnar1−/− mice) leads to increased growth of different 
types of tumors (B16F10 melanoma, 4T1 mammary carcinoma, 
LLC carcinoma, and MCA205 fibrosarcoma) (8, 18, 20, 34, 69) 
and enhanced metastatic processes (20). The strong pro-tumor 
phenotype of Ifnb1−/− mice confirms the hypothesis that the 
expression of all alpha IFNs strongly depends on the previous 
IFN-β expression. Even if pDCS are indeed able to express alpha 
IFNs without previous stimulation, the comparable elevated 
tumor growth in Ifnb1−/− and Ifnar1−/− mice demonstrates its 
irrelevance. Enhanced tumorigenesis in type I IFN-deficient mice 
is accompanied by strong accumulation of neutrophils in primary 
tumors. These neutrophils show reduced cytotoxicity, increased 
pro-angiogenic properties, and are resistant to apoptosis.
TYPe i iFNs iNFLUeNCe THe TURNOveR 
AND THe LiFeSPAN OF NeUTROPHiLS iN 
TUMOR eNviRONMeNT
Neutrophils for long time were believed to be short-living cells. 
This was most probably due to ex vivo manipulation techniques 
that limited the lifespan of these cells. Recently, the perspective is 
changing and there are data demonstrating much longer neutro-
phil lifespan that can reach up to approximately 10–20 days (70). 
Neutrophil homeostasis in the organism is maintained through a 
balance of neutrophil production, release from the BM, and clear-
ance from the circulation (71). The BM serves as a reservoir for 
neutrophils that can be rapidly mobilized in response to inflam-
matory stimuli. However, at steady state, only a small fraction 
of the total BM neutrophil pool is released into circulation (72). 
In the absence of pro-inflammatory stimuli, neutrophils undergo 
spontaneous apoptosis and are phagocyted by tissue macrophages 
(73). Several stimuli can prolong neutrophil survival, including 
infectious factors associated with bacterial infections (LPS) as 
well as colony-stimulating factors, e.g., granulocyte colony-
stimulating factor, G-CSF (74).
Tumors are known to produce the whole spectrum of 
colony-stimulating factors (IL-3, G-CSF, and GM-CSF) (64–66, 
75) that potentially influence proliferation of progenitor cells, 
neutrophil release from BM, and prolongation of their lifespan 
in tissues. Other sources of G-CSF are endothelial cells (76) 
and neutrophils themselves (34). Type I IFNs were shown to 
downregulate G-CSF expression on gene and protein level (20, 
34). G-CSF is known to be a major regulator of neutrophil 
development, mobilization, and differentiation. It has been 
shown to mobilize neutrophils from BM to the blood via STAT3 
activation and regulating CXCL2/CXCR2 axis (20, 77) as well 
as to suppress neutrophil apoptosis (78). Furthermore, recently 
Casbon et al., using a multistage mouse model of breast cancer, 
could show that tumor-derived G-CSF was responsible for both 
the development and activity of immunosuppressive neutrophils 
in cancer (79). Similarly, Spiegel et al. could recently show that 
G-CSF-induced neutrophils act to promote metastasis in 4T1 lung 
metastasis model via inhibition of NK cell-mediated clearance of 
intraluminal tumor cells. Moreover, such neutrophils facilitate 
extravasation of tumor cells into lungs via secretion of IL1β and 
matrix metalloproteinases (80).
Since G-CSF is upregulated in type I IFNs-deficient tumor-
bearing mice (34), this phenomenon could be responsible for 
the observed neutrophil expansion in bloodstream and tumors 
of such mice (18). Generally, TANs are characterized with 
prolonged lifespan comparing to other tissue neutrophils (81). 
Andzinski et al. demonstrated that endogenous type I IFNs influ-
ence neutrophil survival and lifespan. In type I IFNs-deficient 
mice bearing B16F10 melanoma, the neutrophil life span was 
prolonged due to apoptosis suppression. Neutrophilic granulo-
cytes from such Ifnb1−/− tumor-bearing mice expressed higher 
amounts of BCL-xL and showed decreased effector caspase 3 
activity as well as inhibited expression of death receptor Fas (34). 
Fas expression on neutrophils has been shown to be involved 
in spontaneous extrinsic cell death signaling (82). Even though 
Fas ligand-induced apoptosis is considered not to be a major 
mechanism in steady state (83), it has been demonstrated to be 
important under inflammatory conditions, for example, in can-
cer (84). An additional factor that has been revealed to induce 
neutrophil apoptosis is TNFα (85). Notably, type I IFN signaling 
has been shown to increase expression of TNFα by neutrophils 
(8). Decreased neutrophil apoptosis in the absence of endogenous 
type I IFNs could be also due to the decreased production of 
cytotoxic ROS by TANs (34).
TYPe i iFNs iNFLUeNCe NeUTROPHiL 
MiGRATiON iN TUMOR-BeARiNG MiCe
The process of neutrophil migration to the site of inflammation 
depends on the several ligand–receptor interactions, including 
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chemokine sensing and sensing of activated endothelium in 
inflammatory site. Retention of immature neutrophils in BM 
is due to high expression of CXCR4 on the cell surface and its 
interaction with CXCL12 secreted by stromal cells. Attenuation 
of CXCR4 signaling and upregulation of CXCR2 on neutrophils is 
an important mechanism by which these cells are mobilized into 
the circulation under inflammatory conditions (71). Subsequent 
neutrophil migration to tissues is determined by interacting of 
surface chemokine receptors and chemokines forming concen-
tration gradient. Mature neutrophils are characterized by the 
high expression of CXCR2 (86, 87). The ligands of this receptor 
(CXCL8 in humans and CXCL1, CXCL2 in mice) are responsible 
for homing of mature neutrophils into tissues. Lungs, liver, and 
spleen are the major producers of CXCR2 ligands under normal 
conditions and conclude considerable neutrophil marginated pool 
in microvascular bed (88). It is suggested that the high expression 
of CXCR2, CXCR4, and CCR7 ligands in lungs, liver, BM, and 
lymph nodes is one of the reasons responsible for metastases 
homing toward these organs in certain types of cancer (89, 90).
Tumor tissue seems to be a significant source of chemokine 
ligands of CXCR2 (91–93) and forms chemokine gradient 
attracting neutrophils. Low CXCL1 or CXCL2 level in BM and 
high level of these chemokines in the tumor form gradient in 
tumor-bearing mice, thus attracting neutrophils into tumor 
site. Correspondingly, the expression of CXCR2 is the highest 
on neutrophils from BM and blood, and is downregulated after 
reaching the tumor (69). Of note, the migration of neutrophils 
is downregulated by endogenous type I IFNs via suppression 
of chemokines. Expression of CXCL1 and CXCL2 in blood and 
tumor was significantly higher in Ifnb1−/− mice as compared to 
wild-type (WT) controls. On the other hand, the expression of 
CXCL5, which is known to compete with CXCL1 and CXCL2 
for CXCR2-binding site, was upregulated in blood of WT mice. 
This could be responsible for the inhibited migration of neutro-
phils into tumor tissue in WT animals, since they are trapped 
in the blood due to high concentration of CXCL5. Treatment 
of tumor-bearing IFN-deficient mice with recombinant murine 
IFN-β downregulated CXCL1 and CXCL2 expression in blood 
and tumor to the levels observed in control mice (69).
An additional chemokine/receptor axis involved in migration 
of neutrophils into tumor site is CXCL12/CXCR4 axis. This axis has 
also been shown to be downregulated by type I IFNs. Endogenous 
type I IFNs inhibit CXCR4 expression on neutrophils and block 
CXCL12 expression in tumors leading to suppressed migration of 
neutrophils toward the tumor (69).
Rolling, adhesion, and migration of neutrophils to the site 
of inflammation are mediated by the interaction of endothelial 
adhesion molecules and their ligands on leukocytes (94). Mature 
and activated neutrophils are characterized with decreased 
surface expression of l-selectin CD62L (95). Importantly, in the 
absence of endogenous type I IFNs tumor-bearing mice show 
significantly increased percentage of CD62L+ circulating neu-
trophils (8), which could result in increased migration to tumor 
site. All described mechanisms explain the increased migration 
of neutrophils into tumors leading to the enhanced tumor growth 
in IFN-deficient mice.
ReGULATiON OF OXiDATive BURST  
BY TYPe i iFNs
Type I IFNs were shown to regulate the most prominent anti-
tumor feature of neutrophils, i.e., their ability to directly kill 
tumor cells (8). Neutrophil cytotoxicity includes both direct and 
antibody-dependent cell-mediated cytotoxicity (via recognition 
of opsonized cells). Functional activity of neutrophils is deter-
mined by large spectrum of secretory granules and vesicles rather 
than production of proteins de novo. The primary azurophilic 
granules containing myeloperoxidase and other acid hydrolases, 
as well as neutral proteases (cathepsin G, elastases, and col-
lagenases), are responsible for pathogen degradation. Secondary 
(specific) granules are large stores for soluble mediators as well as 
for NADPH oxidase that supports oxidative burst. The tertiary 
granules and secretory vesicles support migration and interaction 
of neutrophils with the environment (96).
Cytotoxicity depends on developmental stage of the cell (63) 
but also on the microenvironment. In animal models, TANs 
show reduction of cytotoxicity in comparison to blood-derived 
neutrophils, indicating further influence of the tumor milieu on 
neutrophil activation and function (8). Type I IFN signaling is 
essential for neutrophils to facilitate some of their functions (63). 
Accordingly, decreased spontaneous production of cytotoxic 
ROS by tumor-infiltrating neutrophils was demonstrated in 
mouse models deficient in endogenous IFNs (34), which was 
linked to significantly reduced cytotoxicity of tumor neutrophils 
in such mice, compared to IFN-sufficient animals. Treatment 
of Ifnb1−/− mice with recombinant IFN-β-restored neutrophil 
cytotoxicity (8).
DeCReASeD NeUTROPHiL 
eXTRACeLLULAR TRAP FORMATiON  
BY NeUTROPHiLS DeFiCieNT iN 
eNDOGeNOUS TYPe i iFNs
Neutrophil extracellular traps consist of nuclear or mitochondrial-
derived web-like DNA strands released from neutrophils that are 
equipped with histones and bactericidal proteins. The process of 
NETs release is called NETosis and it is an unique form of cell 
death. NETosis is a mechanism of distinct killing of extracellular 
pathogens with high local concentration of effector components 
(97). The intracellular components shifted extracellularly become 
a target for macrophages, which destroy attached pathogen as 
well (98). During this process, neutrophils kill extracellular 
pathogens while minimizing damage to the host cells. Tumor 
environment obviously and strongly activates neutrophils and 
initiates NETs release (8). There are conflicting data about the role 
of NETs formation during tumorigenesis. On the one hand, it is 
postulated that released NETs improve efficient tumor cell killing 
by neutrophils (99). On the other hand, there are studies sug-
gesting NETs as a mechanism supporting metastasis formation 
(100). One could speculate that the subsequent fate of trapped 
tumor cells depends on the activation of the neutrophils and their 
ROS release.
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Interferons seem to influence the process of NETosis. Priming 
with IFN-α or IFN-γ with subsequent C5a activation triggers 
release of NETs in mature human neutrophils. Notably, immature 
neutrophils are not able to release NETs in this condition, prob-
ably due to the lack of IFN signaling pathway mediators (63). 
Another animal model study revealed that blood neutrophils 
isolated from type I IFN-deficient tumor-bearing mice display 
significantly lower NETs formation capacity compared to WT 
controls. This is accompanied by less efficient tumor cell killing by 
these cells and was in agreement with observed enhanced tumor 
growth in such mice (8).
SUPPReSSiON OF PRO-ANGiOGeNiC 
PROPeRTieS OF NeUTROPHiLS BY  
TYPe i iFNs
Effective angiogenesis is essential for successful tumor growth. 
One of the developmental hallmarks of a tumor is the induction 
of angiogenesis, i.e., the formation of new blood vessels. Small 
tumors up to a size of 1–2 mm3 can be supplied with oxygen and 
nutrients by the surrounding tissue. For larger tumors, this is no 
longer sufficient. The tumor has to alter its angiogenic phenotype 
and the so-called angiogenic switch – the induction and assembly 
of tumor vasculature – has to take place (101, 102). Interestingly, 
myeloid cells like neutrophils are known to take part in tumor 
vascularization since they are known to be the source of the vari-
ety of pro-angiogenic factors, including VEGF and angiogenic 
chemokines (103). MMPs and other enzymes released by neu-
trophils provide degradation of extracellular matrix and facilitate 
vessel growth (104).
The role of type I IFNs in inhibition of tumor angiogenesis 
has been suggested before (105, 106). Recent data show also the 
significant impact of TANs on angiogenic processes in tumor 
and the important role of type I IFNs in the modulation of these 
processes (18). In Ifnb1−/− mice, considerably higher tumor 
growth was observed, accompanied by boosted angiogenic 
processes. Enhanced content of fully developed functioning 
vessels, completely covered by pericytes, was found. Moreover, 
the number, area and the perimeter of vessels in tumors of such 
mice were significantly higher than in WT mice. Notably, these 
tumors were strongly infiltrated by neutrophils that were found in 
close vicinity of vessels. Neutrophils isolated from Ifnb1−/− mice 
show significantly higher expression of VEGF and MMP9 (18). 
Moreover, CXCR4 was upregulated on these cells. CXCR4, is 
known to be overexpressed in highly vascularized tumors (107, 
108), and its ligand CXCL12 is apparently induced under hypoxic 
conditions in accordance with the triggering of the angiogenic 
switch. Depletion of neutrophils in this model led to reduction 
of number of developed vessels and subsequent retardation of 
tumor growth as compared to untreated animals (18). In vitro 
treatment of TANs isolated from Ifnb1−/− mice with low levels of 
IFN-β restored expression of pro-angiogenic factors to control 
levels (18).
Certain chemokines (CXCL1, CXCL2, CXCL3, CXCL5, 
CXCL6, and CXCL8) are known to mediate angiogenic processes 
through direct activation of endothelial cells via CXCR2 receptor 
or recruit pro-angiogenic immune cells and endothelial progeni-
tors to the neovascular niche (109). Type I IFNs were shown to 
decrease production of some of these chemokines, which 
could serve as an additional antiangiogenic mechanism during 
tumorigenesis (69).
Reactive oxygen species are also considered to be regulators of 
endothelial cell functions. While high amounts of ROS are toxic 
for endothelial cells and reveal antiangiogenic properties, low 
concentrations of NO and H2O2 can serve as intracellular media-
tors of signal transduction to stimulate vascular smooth muscle 
cells to support angiogenesis [reviewed by Irani (110)]. Thereby, 
increased IFN-dependent ROS production by tumor-infiltrating 
neutrophils (34) can additionally exert an antiangiogenic effect.
THe ReGULATiON OF ADAPTive  
iMMUNe ReSPONSeS BY NeUTROPHiLS 
STiMULATeD wiTH TYPe i iFNs
Accumulating data suggest that neutrophils may influence adap-
tive immunity by acting either indirectly (via APCs) or directly 
on T cells. T cells are considered to be key players involved in 
antitumor immunity; yet, many other components of the immune 
system take part in this process. Antigen presentation is an 
important link between innate and adaptive immune responses. 
Two main mechanisms are involved in this process. Fragments of 
intracellular pathogens are presented on MHC class I complex to 
CD8+ cytotoxic T cells. Extracellular pathogens, after phagocyto-
sis and procession, are bound in phagolysosome with MHC class 
II molecules and are presented to CD4+ T-cells (111). The third 
mechanism of antigen presentation, called “cross-presentation,” 
shares features of previous two. In this process, APCs translocate 
extracellular antigen from the endocytic vesicle to the cytosol and 
present it on MHC class I to CD8+ T cells (cross-priming) (112). 
In the last two cases, appropriate activation of APCs is necessary 
to induce effective immune response. In the absence of activating 
stimuli or in anti-inflammatory environment, APCs stimulate 
abortive T-cell responses, which lead to tolerance (113).
All neutrophils constitutively express MHC class I. Murine 
neutrophils, both circulating and resident, are known to 
express MHC class II and can potentially play a role in antigen 
presentation together with macrophages and DCs. To the 
contrary, human circulating neutrophils do not express MHC 
class II under normal conditions, but there is an evidence of 
antigen-presenting function of these cells in certain inflamma-
tory conditions, including autoimmune diseases (114, 115) as 
well as after treatment with GM-CSF (116) or IFN-γ (117). In 
patients with cancer, no MHC class II expression on circulating 
neutrophils was observed (33), arising a question about TANs 
participating in antigen presentation. Immature neutrophils that 
are released from BM as a result of tumor-driven emergency 
myelopoiesis were shown to become activated with cytokines 
released in tumor microenvironment (GM-CSF, IL-4, TNF-α) 
and acquire molecular features characteristic for DCs. Such 
activated DC-like cells express DC-associated surface molecules 
cluster of differentiation CD1a, CD1b, CD1c, MHC class II, and 
costimulatory molecules CD80, CD86, CD40, as well as ICAM-1 
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and CD5. At the same time, these cells downregulate CD15 and 
CD65 expression. Altogether, this leads to effective presentation 
of antigen to CD4+ T cells, thus activating antitumor immune 
responses (118). Recently, Eruslanov et  al. demonstrated that 
neutrophils augment T cell proliferation in a positive-feedback 
loop via upregulation of ICAM-1 and costimulatory molecules 
like CD86, OX40L, and 4-1BBL on the neutrophil surface (32). 
ICAM-1 was also shown to act as a costimulatory molecule 
taking part in antigen presentation to T cells and is crucial for 
T cell activation under conditions where costimulation by CD80 
and CD86 is low (119). High ICAM-1 expression can, therefore, 
induce the activation of cytotoxic CD8+ T cells (120) as well 
as repress the secretion of immunosuppressive IL-10 by CD4+  
T cells (121). Mature neutrophils upregulate ICAM-1 (122) and, 
therefore, can participate in antigen presentation. Importantly, it 
was recently demonstrated that type I IFNs strongly upregulate 
ICAM-1 expression on neutrophils (8).
Type I IFNs support systemic immunity against tumor targets 
by upregulation of MHC class I expression as well as enhance-
ment of cytotoxic T cell responses and activation of NK cells 
(60). They are also known to induce MHC class II expression on 
monocytes (123) as well as to induce cross-priming of CD8+ cells 
against exogenous antigens (112).
Thus, neutrophils are able to influence adaptive immune 
responses, either by directly presenting peptide–MHC class I 
complexes, MHC class II complexes, or by delivering peptides 
to other APCs for presentation. Cross-presentation by these 
cells occurs actually earlier than in professional APCs (31). 
Possibly, neutrophils may directly present peptide to effector T 
cells in  vivo, inducing cytokine production, whereas DCs after 
receiving neutrophil-derived antigenic peptides may migrate to 
lymphoid organs to initiate T cell responses (124).
Apart from activating T cells via antigen presentation, neu-
trophils could attract T cells to the sites of inflammation, e.g., 
growing tumors. CD8+ T cells are attracted to the inflamed tis-
sue via CXCL12 (125). Notably, this chemokine was shown to 
be produced by TANs and downregulated by type I IFNs (18). 
Moreover, neutrophils produce cytokines-stimulating T cell dif-
ferentiation and activation, e.g., IFN-γ or TNF-α. Leschner et al. 
could show that expression of TNF-α is strongly enhanced in 
blood and tumors of tumor-bearing mice (126). Importantly, type 
I IFNs upregulate TNF-α expression in TANs (8), thus regulating 
lymphocyte antitumor responses. On the other hand, peripheral 
blood neutrophils, under specific conditions, e.g., late stage of 
tumor, can also suppress antigen non-specific T cell proliferation 
through the release of arginase-1, TGF-β, and the production of 
ROS (127–129). Expression of ROS was also shown to be stimu-
lated by type I IFNs (8, 34), once again demonstrating the strong 
involvement of this cytokine family in the activation of adaptive 
immune responses leading to the restriction of tumor growth.
THe eFFiCieNCY OF MeTASTATiC 
SPReAD DePeNDS ON NeUTROPHiLS 
AND iS iNHiBiTeD BY TYPe i iFNs
Metastases are associated with unfavorable prognosis in cancer 
(130). Metastatic spread is a complex process that includes cells 
shedding from a primary tumor, their migration in circulation, 
extravasation, and initiation of secondary tumor growth. Recently, 
it was postulated that metastases from primary tumors do not 
migrate and home undirected into sites of secondary growth, but 
are guided by cells that form the so-called pre-metastatic niche 
(19, 29, 131). Major component of the pre-metastatic niche are 
neutrophils. They are apparently controlled by factors produced 
by the primary tumor and are responsible for the preference of 
metastasizing tumor cells to certain organs. Different neutrophil-
mediated mechanisms of metastatic spread are described, includ-
ing promotion of tumor cell extravasation by binding ICAM-1 
on tumor cells (132) or by catching tumor cells via NETs (100).
Endogenous type I IFNs play essential role in modulating 
neutrophil functions in context of metastatic processes. In mice 
lacking endogenous type I IFNs, higher metastatic load was 
observed in the lung as compared to WT animal, which was 
accompanied by strong neutrophil accumulation in this organ 
(18, 20). One of the reasons attributed to this phenomenon was 
the elevated plasma level of G-CSF and increased expression of 
CXCR2 on neutrophils (20). In the absence of endogenous type I 
IFN signaling, neutrophils express more CXCR2 and are capable 
to extravasate more actively to the organs producing high levels of 
CXCL1 or CXCL2. Such organs that are predisposed to metastasis 
formation are lungs, liver, and spleen, as mentioned previously. 
Neutrophils accumulating in pre-metastatic lungs support tumor 
cell extravasation and proliferation by release of pro-metastatic 
proteins, e.g., Bv8, MMP9, S100A8, and S100A9. S100A8 
and S100A9 are known to influence tumor cell proliferation, 
survival, and migration (133) as well as to stimulate migration 
and proliferation of neutrophils themselves. Bv8 induces tumor 
cell extravasation (134) and increases neutrophil accumulation 
within pre-metastatic tissue. MMP9 is responsible for forma-
tion of leaky vasculature in the pre-metastatic lung (131) and 
supports tumor cells survival in this organ. The expression of all 
above factors is significantly enhanced in type I IFN-deficient 
mice and is suppressed by the recombinant IFN treatment (18, 
20). Notably, G-CSF, that is also downregulated by type I IFNs, 
is known to enhance expression of Bv8, S100A8, S100A9, and 
MMP9 in neutrophils and thus might also be directly involved 
in regulating pre-metastatic niche formation (134). Neutrophils 
from IFN-deficient mice show also reduced cytotoxicity against 
tumor cells leading to enhanced metastasis in such mice (20). 
Moreover, Bidwell et al. demonstrated that, in a mouse model, 
early initiated administration of recombinant type I IFNs leads 
to reduced bone metastases and prolonged survival of the host 
(135). This indicates that endogenous type I IFNs effectively sup-
press the formation of pre-metastatic niche on multiple levels.
CLiNiCAL ASPeCTS OF TYPe i  
iFN-MeDiATeD POLARiZATiON  
OF NeUTROPHiLS
The efficacy of type I IFN therapy for various malignancies has 
been investigated for many years. IFN therapy has been clini-
cally evaluated as the treatment of melanoma (136, 137), renal 
cell carcinoma (138, 139), myeloproliferative disorders (140, 
141), lymphomas (142), neuroendocrine tumors (143) as well 
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as vascular neoplasias including pulmonary hemangiomatosis 
(144), infantile hemangiomas (145), Kaposi’s sarcoma (146), and 
malignant hemangiopericytomas (147).
Lately, the role of type I IFNs in modulation of immune cell 
activation in tumor context is getting attention. It is generally 
accepted that immune cells play important role in the regula-
tion of tumor growth. Neutrophils, both circulating and tumor 
associated, represent an independent prognostic marker in a 
broad variety of neoplasias (148, 149); therefore, several stud-
ies aimed to modulate the immune system in order to suppress 
pro-tumoral components and enhance antitumoral immune 
responses. This has determined the increasing interest in type I 
IFN treatment. The evidence that IFNs play a role in neutrophil 
polarization was supported with clinical observations. Recently, 
the increase of ICAM-1 expression on the neutrophils isolated 
from melanoma patients undergoing adjuvant type I IFN 
therapy was shown (8). Notably, the treatment was associated 
with reduced migratory capacity of neutrophils in such patients. 
Blood-derived neutrophils from melanoma patients upon adju-
vant type I IFN treatment significantly downregulate their IL-8 
receptor (CXCR1 and CXCR2) expression. It affects neutrophil 
migration from the BM and is of high clinical importance due 
to poor prognosis for tumor patients with elevated neutrophil 
numbers in blood and tumor. Notably, neutrophil amounts in 
type I IFN treated patients were lower, compared to untreated 
patients (8).
Immunotherapy with alpha IFNs is used for patients with 
different types of malignancies. Nevertheless, its efficacy is 
limited and only a small proportion of patients benefit from 
such treatment. Notably, the level of responsiveness to IFN 
treatment varies among individuals. This might be due to genetic 
polymorphism in type I IFN-related genes that have been shown 
to exert a significant impact on survival and therapy outcome 
in melanoma patients (61). Importantly, humans with impaired 
type I IFN signaling, due to STAT2 deficiency, have been identi-
fied (62). Another reason for impaired therapy response could be 
a suppression of pathways involved in IFN signal transduction 
in different microenvironment conditions, e.g., in GM-CSF 
presence (63). One of the factors reflecting the sensitivity of 
neutrophils to IFN-α therapy is a study by Azuma et al. showing a 
favorable survival predictive response correlated with a decrease 
FiGURe 1 | Type i interferon (iFN)-dependent regulation of neutrophil polarization in cancer. Neutrophils may be divided into N1 antitumor and N2 
pro-tumor cells in tumor situation. The activation and differentiation of these cells during tumorigenesis is determined by the growth factor and cytokine milieu in the 
tumor. Type I IFNs are potent drivers of the transition into antitumor N1 phenotype.
TABLe 1 | Type i iFN-dependent regulation of neutrophil polarization in 
cancer.
Sufficient  
type i iFN 
signaling
impaired 
type i iFN 
signaling
Polarization of neutrophils N1 
anti-tumor
N2 pro- 
tumor
THe TURNOveR AND THe LiFeSPAN OF NeUTROPHiLS
Neutrophil expansion in bloodstream and tumor ↓ ↑
Expression of G-CSF by neutrophils ↑ ↓
Expression of pro-apoptotic factors by neutrophils 
(caspase 3, TNFα, Fas, ROS production)
↑ ↓
Expression of antiapoptotic factors by neutrophils (Bcl-XL) ↓ ↑
MiGRATiON OF NeUTROPHiLS TO THe TUMOR SiTe
Neutrophil expansion in bloodstream and tumor ↓ ↑
CXCR2 – CXCL1, CXCL2 axis activation ↓ ↑
CXCR4 – CXCL12 axis activation ↓ ↑
CD62L expression on circulating neutrophils ↓ ↑
KiLLiNG OF TUMOR CeLLS
Neutrophil cytotoxicity against tumor cells ↑ ↓
ROS production by TAN ↑ ↓
Neutrophil extracellular traps formation ↑ ↓
ReGULATiON OF ADAPTive iMMUNe ReSPONSe
Expression of co-stimulatory molecules (ICAM-1) ↑ ↓
Expression of cytokines (TNFα) ↑ ↓
ANGiOGeNeSiS AT THe TUMOR SiTe
The number of fully developed vessels in the tumor ↓ ↑
Expression of VEGF, MMP9 by TAN ↓ ↑
CXCR2 – CXCL1, CXCL2 axis activation ↓ ↑
CXCR4 – CXCL12 axis activation ↓ ↑
ROS production by TAN ↑ ↓
FORMATiON OF THe PRe-MeTASTATiC NiCHe
Metastatic load in organs ↓ ↑
Accumulation of neutrophils in metastatic organs ↓ ↑
Expression of pro-metastatic proteins  
(Bv8, S100, and MMP9)
↓ ↑
CXCR2 – CXCL1, CXCL2 axis activation ↓ ↑
Neutrophils may be biased into N1 antitumor and N2 pro-tumor cells in tumor situation. 
The activation and differentiation of these cells during tumorigenesis is determined by 
the growth factor and cytokine milieu in the tumor. Type I interferons are potent drivers 
of the transition into antitumor N1 phenotype.
GCSF, granulocyte colony-stimulating factor; TNFα, tumor necrosis factor alpha; 
ROS, reactive oxygen species; TAN, tumor-associated neutrophils; VEGF, vascular 
endothelial growth factor; MMP9, matrix metallopeptidase 9.
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CONCLUDiNG ReMARKS
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of neutrophils in tumor-bearing hosts. IFNs drive neutrophils to 
an antitumor and antimetastatic phenotype in numerous ways: 
due to restriction of neutrophil survival and migration to tumor 
site, via enhancement of neutrophil cytotoxicity and NETs for-
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